Ensuring SIBO Breath Test Results Match Clinician Clinical Impressions

In this episode, I sit down with Gary Stapleton to unpack the complexity of small intestinal bacterial overgrowth and why it is so often overlooked in clinical practice. We discuss the true prevalence of SIBO, how it contributes to both digestive and systemic symptoms, and why accurate diagnosis is essential for meaningful treatment outcomes.
Gary shares his expertise on breath testing as the cornerstone of proper SIBO diagnosis. We break down the differences between glucose, lactulose, and fructose substrates, explain when each should be used, and highlight common testing errors that can lead to confusion or misdiagnosis. This portion of the conversation brings clarity to a topic that is frequently misunderstood.

We also explore how SIBO overlaps with other gastrointestinal and systemic conditions and why an individualized approach matters. This episode provides a practical framework for understanding SIBO testing and treatment and is essential listening for anyone looking to move beyond trial and error and toward precision based gut health care. Key takeaways:

• SIBO is characterized by an abnormal increase of bacteria in the small intestine, often leading to digestive and systemic health issues.

• Accurate testing and proper preparation are crucial for a reliable diagnosis of SIBO.

• The choice of substrate (glucose, lactulose, fructose) plays a critical role in breath testing accuracy.

• Understanding the symptoms and co-occurring conditions of SIBO can guide effective treatment strategies.

• Collaboration between laboratories and healthcare practitioners is essential for optimal patient care and treatment outcomes.

More About Gary Stapleton: Gary Stapleton is the founder and Chief Executive Officer of Aerodiagnostics, LLC, where he focuses on advancing diagnostic accuracy and improving clinical decision making in functional and gastrointestinal health. With decades of leadership experience in healthcare diagnostics and pharmaceuticals, Gary brings a deep understanding of how precision testing can transform patient outcomes.

Prior to founding Aerodiagnostics, Gary held senior executive roles across major healthcare organizations, including Chief Operating Officer at Calloway Laboratories, Vice President of Sales and Marketing at Bausch & Lomb, and leadership positions at Caris Life Sciences and Lerner Medical Devices. Earlier in his career, he spent 14 years at AstraZeneca, where he played a key role in the launch and commercialization of multiple blockbuster therapies.

A former member of the United States Marine Corps, Gary combines disciplined leadership with a passion for innovation in healthcare. He holds an undergraduate degree from Long Island University and an MBA, and founded Aerodiagnostics.

• Website
• Instagram

Connect with me!

• Website

• Instagram

• Facebook

• YouTube